Kiwi drug company AFT looks at medical cannabis opportunities as referendum nears
Posted on April 21 2019
New Zealand drug company AFT Pharmaceuticals is planning to expand into medical cannabis should the country vote in favour of drug law reform in next year's referendum, its founder says.
Started 20 years ago in a garage by husband and wife team Marree and Hartley Atkinson using only 50K start-up capital, in late 2015 AFT listed on the NZ & Aussie stock-market raising $33.2 million dollars which is it plans to spend on researching new and emerging markets, one of which they are hoping may be Medicinal Cannabis.
The company currently markets the 100+ products, many for pain relief with the most popular being Maxigesic, a patented combination of paracetamol and ibuprofen. It's sold in 15 countries and licensed in about 130.